Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip S Pang

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Antiviral Therapy|February 8, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitorDavid Nelson, Eric M Yoshida, Matthew S Paulson, et al.
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
Gastroenterology|December 6, 2014
Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genomeNam-Joon Cho, Choongho Lee, Phillip S Pang, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Blood Advances|February 20, 2020
Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantationHannah Imlay, Hu Xie, Wendy M Leisenring, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
The New England Journal of Medicine|October 27, 2021
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Antiviral Therapy|February 8, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitorDavid Nelson, Eric M Yoshida, Matthew S Paulson, et al.
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
Gastroenterology|December 6, 2014
Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genomeNam-Joon Cho, Choongho Lee, Phillip S Pang, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Blood Advances|February 20, 2020
Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantationHannah Imlay, Hu Xie, Wendy M Leisenring, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
The New England Journal of Medicine|October 27, 2021
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
Pageof 5